NASDAQ:APVO - Aptevo Therapeutics Stock Price, Forecast & News

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Aptevo Therapeutics Inc (NASDAQ:APVO) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.24) by $0.01. The biotechnology company earned $9.01 million during the quarter, compared to the consensus estimate of $8.05 million. Aptevo Therapeutics had a negative net margin of 156.03% and a negative return on equity of 171.99%. View Aptevo Therapeutics' Earnings History.

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aptevo Therapeutics.

2 brokerages have issued twelve-month price objectives for Aptevo Therapeutics' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Aptevo Therapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 341.2% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.

News coverage about APVO stock has trended very negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aptevo Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Aptevo Therapeutics.

Some companies that are related to Aptevo Therapeutics include Marinus Pharmaceuticals (MRNS), Aptinyx (APTX), vTv Therapeutics (VTVT), OASMIA PHARMACE/ADR (OASM), Gemphire Therapeutics (GEMP), NeuBase Therapeutics (NBSE), CELYAD SA/ADR (CYAD), Millendo Therapeutics (MLND), Clearside Biomedical (CLSD), Otonomy (OTIC), CV Sciences (CVSI), Aduro BioTech (ADRO), Stealth BioTherapeutics (MITO), Axovant Gene Therapies (AXGT) and AVEO Pharmaceuticals (AVEO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), AVEO Pharmaceuticals (AVEO), Exelixis (EXEL) and Adamis Pharmaceuticals (ADMP).

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APVO stock can currently be purchased for approximately $0.68.

Aptevo Therapeutics has a market capitalization of $30.79 million and generates $23.07 million in revenue each year. The biotechnology company earns $-53,690,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.View Additional Information About Aptevo Therapeutics.

The official website for Aptevo Therapeutics is http://www.aptevotherapeutics.com/.

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]